158 related articles for article (PubMed ID: 2538225)
21. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
22. B cells induce apoptosis via a novel mechanism in fibroblasts infected with mouse hepatitis virus.
Nishioka WK; Welsh RM
Nat Immun; 1993; 12(3):113-27. PubMed ID: 8392406
[TBL] [Abstract][Full Text] [Related]
23. Analysis of rat natural killer cytotoxic factor (NKCF) produced by rat NK cell lines and the production of a murine monoclonal antibody that neutralizes NKCF.
Ortaldo JR; Winkler-Pickett R; Morgan AC; Woodhouse C; Kantor R; Reynolds CW
J Immunol; 1987 Nov; 139(9):3159-65. PubMed ID: 3668253
[TBL] [Abstract][Full Text] [Related]
24. Rapid killing of actinomycin D-treated tumor cells by human monocytes. II. Cytotoxicity is independent of secretion of reactive oxygen intermediates and is suppressed by protease inhibitors.
Colotta F; Bersani L; Lazzarin A; Poli G; Mantovani A
J Immunol; 1985 May; 134(5):3524-31. PubMed ID: 4038989
[TBL] [Abstract][Full Text] [Related]
25. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.
Rappa G; Lorico A; Sartorelli AC
Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008
[TBL] [Abstract][Full Text] [Related]
26. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
[TBL] [Abstract][Full Text] [Related]
27. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
28. Natural cytotoxicity against mouse hepatitis virus-infected cells. II. A cytotoxic effector cell with a B lymphocyte phenotype.
Welsh RM; Haspel MV; Parker DC; Holmes KV
J Immunol; 1986 Feb; 136(4):1454-60. PubMed ID: 3003199
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
Hinuma S; Naruo K; Shiho O; Tsukamoto K
Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
[TBL] [Abstract][Full Text] [Related]
30. The selective growth of murine newborn-derived suppressor cells and their probable mode of action.
Jadus MR; Parkman R
J Immunol; 1986 Feb; 136(3):783-92. PubMed ID: 2934478
[TBL] [Abstract][Full Text] [Related]
31. Drug-dependent cellular cytotoxicity mediated by polymorphonuclear leukocytes.
Ikenami M; Mizuno D; Yamazaki M
Jpn J Cancer Res; 1985 Jul; 76(7):637-43. PubMed ID: 3928561
[TBL] [Abstract][Full Text] [Related]
32. Suppression of in vitro maintenance and interferon-mediated augmentation of natural killer cell activity by adherent peritoneal cells from normal mice.
Brunda MJ; Taramelli D; Holden HT; Varesio L
J Immunol; 1983 Apr; 130(4):1974-9. PubMed ID: 6187831
[TBL] [Abstract][Full Text] [Related]
33. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
34. Studies on the mechanism of natural killer cytotoxicity. III. Activation of NK cells by interferon augments the lytic activity of released natural killer cytotoxic factors (NKCF).
Wright SC; Bonavida B
J Immunol; 1983 Jun; 130(6):2960-4. PubMed ID: 6189908
[TBL] [Abstract][Full Text] [Related]
35. Tumor necrosis factor production by human monocytes is a regulated event: induction of TNF-alpha-mediated cellular cytotoxicity by endotoxin.
Kornbluth RS; Edgington TS
J Immunol; 1986 Oct; 137(8):2585-91. PubMed ID: 3760568
[TBL] [Abstract][Full Text] [Related]
36. Tuftsin: a naturally occurring immunopotentiating factor. I. In vitro enhancement of murine natural cell-mediated cytotoxicity.
Phillips JH; Babcock GF; Nishioka K
J Immunol; 1981 Mar; 126(3):915-21. PubMed ID: 6893996
[TBL] [Abstract][Full Text] [Related]
37. Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection.
Stein-Streilein J; Bennett M; Mann D; Kumar V
J Immunol; 1983 Dec; 131(6):2699-704. PubMed ID: 6644021
[TBL] [Abstract][Full Text] [Related]
38. Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
Pommier Y; Kerrigan D; Covey JM; Kao-Shan CS; Whang-Peng J
Cancer Res; 1988 Feb; 48(3):512-6. PubMed ID: 2825977
[TBL] [Abstract][Full Text] [Related]
39. The role of anti-asialo GM1 antibody-sensitive cells in the implementation of tumor-specific T cell-mediated immunity in vivo.
Yoshioka T; Sato S; Fujiwara H; Hamaoka T
Jpn J Cancer Res; 1986 Aug; 77(8):825-32. PubMed ID: 3093429
[TBL] [Abstract][Full Text] [Related]
40. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
